香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） MEDICARE 更換核數師 本公佈乃天安卓健有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯 合交易所有限公司證券上市規則第13.51(4)條而作出。 本公司董事會（「董事會」）謹此宣佈，香港立信德豪會計師事務所有限公司（「立信德 豪」）已辭任本公司核數師，自二零二五年十月二十四日起生效。董事會經本公司審 核委員會（「審核委員會」）推薦，已委任德勤 • 關黃陳方會計師行（「德勤」）為本公司 新任核數師，自二零二五年十月二十四日起生效，以填補立信德豪辭任後的臨時空 缺，並任職直至本公司下屆股東週年大會結束為止。 是次更換本公司核數師乃由董事會經審核委員會推薦而決定，旨在使本公司與其最 終控股公司及中間控股公司（現均採用德勤作為其核數師）的審核安排保持一致，從 而提升審核服務之效率，此舉符合本公司及本公司股東（「股東」）整體之最佳利益。 立信德豪已於其辭任函中 ...

Core Insights - The global equipment manufacturing industry is focusing on Shandong Heavy Industry in Qingdao, China, as it hosts the global partner conference with nearly 2,500 partners from 140 countries, showcasing around 300 products and covering an exhibition area of 30,000 square meters [1] - Shandong Heavy Industry reported impressive financial results for the first nine months of 2025, achieving nearly 440 billion yuan in revenue, a year-on-year increase of over 9%, with overseas business accounting for 60% of total revenue, highlighting the company's deepening globalization strategy [1] Globalization Strategy - Shandong Heavy Industry has moved beyond traditional trade to establish a new model of diversified business collaboration in international markets, with 30% of overseas revenue coming from European and American industries and another 30% from localized manufacturing and sales of domestic products [3] - The company has demonstrated strong performance across its subsidiaries, with China National Heavy Duty Truck's export sales reaching 111,000 units, a 24.5% increase, and Weichai Group's engine exports growing by 30% [5][5] Localization and Innovation - The company emphasizes a "deep cultivation of international markets" strategy, focusing on local teams, management, manufacturing, and R&D to address the complexities of the global environment [5] - Weichai's internationalization index has reached 40.93%, with all overseas acquisitions being profitable, driven by a strategy of synergy, localization, and unified goals [7] Technological Advancements - Shandong Heavy Industry invests heavily in R&D, maintaining a research intensity of 4.2%, with an expected investment of 13.6 billion yuan in 2024, leading to significant advancements in engine technology and vehicle design [9] - The company has introduced AI-powered machinery and customized products for specific markets, enhancing its global competitiveness [9] Collaborative Ecosystem - The "We Are One" philosophy fosters a unique collaborative innovation ecosystem, enabling rapid responses to customer needs through supply chain cooperation and shared resources among subsidiaries [10] - This collaborative model provides Shandong Heavy Industry with a competitive edge over Western companies, allowing for faster technological responses [10] Redefining Globalization - Shandong Heavy Industry's globalization practices are redefining the paradigm of Chinese equipment manufacturing, focusing on systemic outputs of technology, management, brand, and culture, rather than just product movement [12] - The company's approach, centered on deep localization, technological innovation, and cooperative win-win strategies, opens new growth avenues and offers significant insights for the high-quality development of Chinese manufacturing [12]

Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].

Group 1 - The company Tianan Health (00383) announced a share buyback plan, intending to repurchase 200,000 shares at a total cost of HKD 18.4 million [1] - The buyback price is set at HKD 0.92 per share [1]

Core Viewpoint - Tianan Health (00383) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 200,000 shares at a total cost of HKD 184,000 [1] - The buyback price is set at HKD 0.92 per share [1] - The buyback is scheduled for October 10, 2025 [1]

Core Viewpoint - Tianan Health (00383.HK) announced a share buyback of 200,000 shares at a cost of HKD 184,000 on October 10 [1] Group 1 - The company executed a buyback program, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 184,000, reflecting the company's financial strategy [1] - The number of shares repurchased was 200,000, which may influence the stock's liquidity and market perception [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 00383 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | | 已發行股份（不包括庫存股份）數 | | 行股份（不包括庫存股 | | 庫存股份數目 | | | | | | | 目 | | 份） ...

Group 1 - The article reports on share buybacks conducted by various companies on October 2, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 812,000 shares for a total of 550 million, representing 0.725% of its total share capital for the year [2] - Other notable companies involved in the buyback include Hang Seng Bank, which repurchased 200,000 shares for 23.94 million, and Cloud Factory, which repurchased 2 million shares for 9.59 million [2] Group 2 - The total number of shares repurchased by Tencent Holdings year-to-date is 66.625 million [2] - Hang Seng Bank's cumulative repurchase for the year stands at 8.73 million shares [2] - Cloud Factory's cumulative repurchase for the year is 6.109 million shares, indicating a significant buyback activity [2]

Core Viewpoint - Tianan Health (00383) announced a share buyback plan, intending to repurchase 5,000 shares at a total cost of HKD 4,500, with each share priced at HKD 0.9 [1] Summary by Category - **Company Actions** - The company will execute a buyback of 5,000 shares [1] - The total expenditure for the buyback is set at HKD 4,500 [1] - The buyback price per share is established at HKD 0.9 [1]

Core Viewpoint - Tianan Health (00383.HK) announced a share buyback on October 2, spending HKD 4,500 to repurchase 5,000 shares [1] Summary by Category - **Company Actions** - The company executed a buyback of 5,000 shares at a cost of HKD 4,500 on October 2 [1]